1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Use of Anticoagulant and Antiplatelet Agents in Patients with Subarachnoid Hemorrhage who Undergo Aneurysm Coiling and Ventriculosomy (n = 24)
Medication n % IV administered heparin, during procedure 23 96 IV administered abciximab, during procedure 2 8 SC administered heparin or enoxaparin, after procedure 7 29 PO ASA, after procedure 10 42 PO clopidogrel, after procedure 2 8
Note.—SC indicates subcutaneously; PO, per os; ASA, acetylsalicylic acid.